JP2001511450A5 - - Google Patents

Download PDF

Info

Publication number
JP2001511450A5
JP2001511450A5 JP2000504859A JP2000504859A JP2001511450A5 JP 2001511450 A5 JP2001511450 A5 JP 2001511450A5 JP 2000504859 A JP2000504859 A JP 2000504859A JP 2000504859 A JP2000504859 A JP 2000504859A JP 2001511450 A5 JP2001511450 A5 JP 2001511450A5
Authority
JP
Japan
Prior art keywords
formulation
tiagabine
plasma concentration
hours
rate controlling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000504859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001511450A (ja
Filing date
Publication date
Priority claimed from IE19970588A external-priority patent/IE970588A1/en
Application filed filed Critical
Priority claimed from PCT/IE1998/000067 external-priority patent/WO1999006045A1/en
Publication of JP2001511450A publication Critical patent/JP2001511450A/ja
Publication of JP2001511450A5 publication Critical patent/JP2001511450A5/ja
Pending legal-status Critical Current

Links

JP2000504859A 1997-08-01 1998-07-30 チアガビンを含有する制御放出性の医薬組成物 Pending JP2001511450A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5443297P 1997-08-01 1997-08-01
IE19970588A IE970588A1 (en) 1997-08-01 1997-08-08 Controlled release pharmaceutical compositions containing tiagabine
IE970588 1997-08-08
IE60/054,432 1997-08-08
PCT/IE1998/000067 WO1999006045A1 (en) 1997-08-01 1998-07-30 Controlled release pharmaceutical compositions containing tiagabine

Publications (2)

Publication Number Publication Date
JP2001511450A JP2001511450A (ja) 2001-08-14
JP2001511450A5 true JP2001511450A5 (enExample) 2006-01-05

Family

ID=26320083

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000504859A Pending JP2001511450A (ja) 1997-08-01 1998-07-30 チアガビンを含有する制御放出性の医薬組成物

Country Status (10)

Country Link
EP (1) EP0991409B1 (enExample)
JP (1) JP2001511450A (enExample)
AT (1) ATE212550T1 (enExample)
AU (1) AU8643698A (enExample)
CA (1) CA2299464C (enExample)
DE (1) DE69803670T2 (enExample)
DK (1) DK0991409T3 (enExample)
ES (1) ES2172179T3 (enExample)
PT (1) PT991409E (enExample)
WO (1) WO1999006045A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002325404B2 (en) * 1998-01-22 2006-02-02 Abbott Laboratories Extended Release Tiagabine Formulations with Reduced Side-effects
ZA99407B (en) * 1998-01-22 1999-07-20 Abbott Lab Extended release tiagabine formulations with reduced side-effects.
RU2220715C2 (ru) * 1999-08-04 2004-01-10 Яманоути Фармасьютикал Ко., Лтд. Стабильная пероральная, образующая гидрогель, фармацевтическая композиция, способ ее получения, способ предотвращения изменений высвобождения лекарственного средства, способ увеличения физической стабильности пероральной композиции
KR100510270B1 (ko) * 2002-11-29 2005-08-26 센츄론(주) 펠렛타이저를 이용한 서방성 제제의 제조방법
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
AU2004222339A1 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CA2914365C (en) 2013-06-05 2022-03-15 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5750140A (en) * 1994-05-20 1998-05-12 Novo Nordisk A/S Transdermal delivery of tiagabine
AU707508B2 (en) * 1995-05-05 1999-07-15 Novo Nordisk A/S Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
JP2000511538A (ja) * 1996-05-24 2000-09-05 スミスクライン・ビーチャム・コーポレイション 鎮咳剤としてのｇａｂａ取り込み阻害剤の使用
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders

Similar Documents

Publication Publication Date Title
JP3964465B2 (ja) 粘膜表面への、薬学的化合物の送達に適する薬学的キャリアデバイス
EP1555022B1 (en) Sustained release formulation of acetaminophen and tramadol
IE970588A1 (en) Controlled release pharmaceutical compositions containing tiagabine
JP4619894B2 (ja) 粘膜表面への、薬剤化合物の送達に適する薬剤キャリアデバイス
AU2002226955B2 (en) Pharmaceutical dosage form with multiple coatings
AU750617B2 (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
CN103813807B (zh) 易服用性固体制剂
TWI302460B (en) Pharmaceutical compositions and use thereof
CN101534792A (zh) 包含氧可酮的粒剂和口腔崩解片剂
CN101969931A (zh) 包含霉酚酸的调节释放药物组合物及其方法
JPH10203983A (ja) 結腸送逹のための多層腸溶性ポリマーコーティングを有するビサコジル投与形態
CA1181695A (en) Nitrofurantoin dosage form
JP2006507276A (ja) 放出制御組成物
MD3684344T2 (ro) Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
US20030099710A1 (en) Granule modulating hydrogel system
US6994871B2 (en) Once a day antihistamine and decongestant formulation
JP2001511450A5 (enExample)
JP4953673B2 (ja) 経口投与剤
MXPA05004338A (es) Composiciones de liberacion sostenida que contienen alfuzosin.
WO2009027786A2 (en) Matrix dosage forms of varenicline
AU2004258953B2 (en) Antibiotic product, use and formulation thereof
JP6688819B2 (ja) 易服用性固形製剤
AU2004258949A1 (en) Antibiotic product, use and formulation thereof
WO2011018246A2 (en) Controlled release paliperidone composition
US20040228918A1 (en) Granule modulating hydrogel system